Skip to content
OpenCapital
Get started

Aquestive Therapeutics, Inc. AQST Q1 2026 earnings

Reported May 13, 2026 · After market close

Revenue$14.4MBeat by $3.6MDiluted EPS-$0.07Beat by $0.07
Revenue estimate$10.9M
EPS estimate-$0.14

Next report

Aug 10, 2026 (In 4 weeks)
Revenue estimate$11.4M
EPS estimate-$0.10

Financials

Q1 2026

Income statement

See full
Revenue$14.4M+65.7%
Gross profit$11.0M+117%
Operating income-$4.2M+78.3%
Net income-$8.1M+64.9%
EPS (diluted)-$0.07+70.8%

Balance sheet

See full
Cash & equivalents$110.7M+61.3%
Total debt$64.4M+7.4%
Total equity-$34.1M+44.1%
Total assets$141.1M+38.0%

Cash flow

See full
Operating cash flow-$14.8M+36.7%
CapEx$52.0K-61.5%
Free cash flow-$14.9M+36.9%

Valuation & ratios

Valuation

as of 07/10/26
See full
Market cap$531.98M+76.6%
Enterprise value$485.6M+65.5%
P/S10.6×+5.0×

Profitability

See full
Gross margin63.5%-4.9pp
Operating margin-111.2%+96.3pp
Net margin-137.1%+80.7pp
FCF margin-88.2%-2.2pp

Returns & leverage

See full
Current ratio4.1×-0.8×

Segments

By product

See full
Manufacture and supply revenue$8.8M—
License and royalty revenue a$5.4M—
Co-development and research fees$258.0K—
Proprietary product revenue, net-—

By segment

See full
Reportable Segment$14.4M+65.7%

By geography

See full
United States$13.2M—

Versus estimates

Revenue

Q1 2026$14.4MBeat by $3.6M
Q4 2025$13.0MMiss by $271.4KQ3 2025$12.8MMiss by $136.5KQ2 2025$10.0MMiss by $2.2MQ1 2025$8.7MMiss by $3.5MQ4 2024$11.9MMiss by $1.2M

Diluted EPS

Q1 2026-$0.07Beat by $0.07
Q4 2025-$0.26Miss by $0.13Q3 2025-$0.14Miss by $0.03Q2 2025-$0.14Beat by $0.04Q1 2025-$0.24Miss by $0.07Q4 2024-$0.19Miss by $0.05

Ask the moment Aquestive Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Aquestive Therapeutics, Inc. report Q1 2026 earnings?
Aquestive Therapeutics, Inc. (AQST) reported Q1 2026 earnings on May 13, 2026 after market close.
What were Aquestive Therapeutics, Inc.'s Q1 2026 revenue and EPS?
Aquestive Therapeutics, Inc. reported revenue of $14.4M and diluted EPS of $-0.07 for Q1 2026.
Did Aquestive Therapeutics, Inc. beat estimates in Q1 2026?
Revenue beat the consensus estimate of $10.9M by $3.6M. EPS beat the consensus estimate of $-0.14 by $0.07.
How did Aquestive Therapeutics, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 65.7% from $8.7M a year earlier and diluted EPS grew 70.8% from $-0.24.
Where can I find Aquestive Therapeutics, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001398733-26-000029) and the 10-Q periodic report (0001398733-26-000030) directly on SEC EDGAR. The filing index links above go to sec.gov.